S&P 500   3,322.00 (+0.47%)
DOW   27,136.10 (+1.15%)
QQQ   270.94 (+0.21%)
AAPL   438.60 (-0.01%)
MSFT   212.61 (-0.32%)
FB   249.04 (-0.32%)
GOOGL   1,478.36 (+0.34%)
AMZN   3,206.16 (+2.15%)
NVDA   451.26 (+0.48%)
CGC   19.27 (-0.26%)
BABA   265.72 (+1.34%)
TSLA   1,487.82 (+0.06%)
MU   50.80 (-0.97%)
GE   6.32 (+2.93%)
AMD   85.21 (+0.20%)
T   29.82 (-0.63%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.36 (-2.14%)
NFLX   503.32 (-1.24%)
DIS   127.65 (+8.83%)
BAC   25.42 (+1.64%)
BA   173.89 (+5.34%)
S&P 500   3,322.00 (+0.47%)
DOW   27,136.10 (+1.15%)
QQQ   270.94 (+0.21%)
AAPL   438.60 (-0.01%)
MSFT   212.61 (-0.32%)
FB   249.04 (-0.32%)
GOOGL   1,478.36 (+0.34%)
AMZN   3,206.16 (+2.15%)
NVDA   451.26 (+0.48%)
CGC   19.27 (-0.26%)
BABA   265.72 (+1.34%)
TSLA   1,487.82 (+0.06%)
MU   50.80 (-0.97%)
GE   6.32 (+2.93%)
AMD   85.21 (+0.20%)
T   29.82 (-0.63%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.36 (-2.14%)
NFLX   503.32 (-1.24%)
DIS   127.65 (+8.83%)
BAC   25.42 (+1.64%)
BA   173.89 (+5.34%)
S&P 500   3,322.00 (+0.47%)
DOW   27,136.10 (+1.15%)
QQQ   270.94 (+0.21%)
AAPL   438.60 (-0.01%)
MSFT   212.61 (-0.32%)
FB   249.04 (-0.32%)
GOOGL   1,478.36 (+0.34%)
AMZN   3,206.16 (+2.15%)
NVDA   451.26 (+0.48%)
CGC   19.27 (-0.26%)
BABA   265.72 (+1.34%)
TSLA   1,487.82 (+0.06%)
MU   50.80 (-0.97%)
GE   6.32 (+2.93%)
AMD   85.21 (+0.20%)
T   29.82 (-0.63%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.36 (-2.14%)
NFLX   503.32 (-1.24%)
DIS   127.65 (+8.83%)
BAC   25.42 (+1.64%)
BA   173.89 (+5.34%)
S&P 500   3,322.00 (+0.47%)
DOW   27,136.10 (+1.15%)
QQQ   270.94 (+0.21%)
AAPL   438.60 (-0.01%)
MSFT   212.61 (-0.32%)
FB   249.04 (-0.32%)
GOOGL   1,478.36 (+0.34%)
AMZN   3,206.16 (+2.15%)
NVDA   451.26 (+0.48%)
CGC   19.27 (-0.26%)
BABA   265.72 (+1.34%)
TSLA   1,487.82 (+0.06%)
MU   50.80 (-0.97%)
GE   6.32 (+2.93%)
AMD   85.21 (+0.20%)
T   29.82 (-0.63%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.36 (-2.14%)
NFLX   503.32 (-1.24%)
DIS   127.65 (+8.83%)
BAC   25.42 (+1.64%)
BA   173.89 (+5.34%)
Log in

NASDAQ:PRAHPRA Health Sciences Stock Price, Forecast & News

$108.24
+1.61 (+1.51 %)
(As of 08/5/2020 03:48 PM ET)
Add
Compare
Today's Range
$106.53
Now: $108.24▼
$108.74
50-Day Range
$93.45
MA: $98.81▼
$107.97
52-Week Range
$58.67
Now: $108.24▼
$113.32
Volume10,585 shs
Average Volume232,226 shs
Market Capitalization$6.90 billion
P/E Ratio29.57
Dividend YieldN/A
Beta1.1
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More
PRA Health Sciences logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.22 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
Previous Symbol
CUSIPN/A
CIK1613859
Webwww.prahs.com
Phone919-786-8200

Debt

Debt-to-Equity Ratio1.14
Current Ratio0.93
Quick Ratio0.93

Price-To-Earnings

Trailing P/E Ratio29.57
Forward P/E Ratio29.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.07 billion
Price / Sales2.25
Cash Flow$6.97 per share
Price / Cash Flow15.53
Book Value$17.23 per share
Price / Book6.28

Profitability

EPS (Most Recent Fiscal Year)$4.80
Net Income$243.02 million
Net Margins7.66%
Return on Equity27.59%
Return on Assets8.39%

Miscellaneous

Employees17,500
Outstanding Shares63,720,000
Market Cap$6.90 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$108.24
+1.61 (+1.51 %)
(As of 08/5/2020 03:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRAH stock has increased by 22.1% and is now trading at $108.24.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PRA Health Sciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PRA Health Sciences.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for PRA Health Sciences.

How can I listen to PRA Health Sciences' earnings call?

PRA Health Sciences will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings data on Thursday, April, 30th. The medical research company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.01 by $0.04. The medical research company earned $783.71 million during the quarter, compared to analysts' expectations of $749.61 million. PRA Health Sciences had a return on equity of 27.59% and a net margin of 7.66%. The business's revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.10 EPS.
View PRA Health Sciences' earnings history.

What price target have analysts set for PRAH?

11 equities research analysts have issued 1 year price objectives for PRA Health Sciences' shares. Their forecasts range from $82.00 to $120.00. On average, they anticipate PRA Health Sciences' share price to reach $101.00 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

News coverage about PRAH stock has been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PRA Health Sciences earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.
View the latest news about PRA Health Sciences.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 1,160,000 shares, a decline of 18.3% from the June 30th total of 1,420,000 shares. Based on an average daily trading volume, of 396,500 shares, the short-interest ratio is currently 2.9 days. Approximately 1.8% of the company's stock are short sold.
View PRA Health Sciences' Current Options Chain.

Who are some of PRA Health Sciences' key competitors?

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Applied Materials (AMAT), Veeva Systems (VEEV), Walt Disney (DIS), Paypal (PYPL), Home Depot (HD), Lam Research (LRCX) and UnitedHealth Group (UNH).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include NN Investment Partners Holdings N.V. (2.32%), NN Investment Partners Holdings N.V. (2.30%), Retirement Systems of Alabama (0.28%), Mackay Shields LLC (0.24%), Swiss National Bank (0.22%) and Reilly Financial Advisors LLC (0.18%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr, Michael J Bonello and Pra Investors LP Kkr.
View institutional ownership trends for PRA Health Sciences.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, UBS Group AG, FDx Advisors Inc., Russell Investments Group Ltd., Three Peaks Capital Management LLC, Carnegie Capital Asset Management LLC, Envestnet Asset Management Inc., and Executive Wealth Management LLC. Company insiders that have sold PRA Health Sciences company stock in the last year include Fund Holdings LP Kkr, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was purchased by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Mackay Shields LLC, Swiss National Bank, Dupont Capital Management Corp, Strs Ohio, Assenagon Asset Management S.A., and Brinker Capital Inc..
View insider buying and selling activity for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $108.24.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.90 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.